What is it about?

We assessed the safety of empagliflozin in patients with type 2 diabetes and moderate-to-severe chronic kidney disease across across patients enrolled in 19 clinical trials. Use of empagliflozin in these patients raised no new safety concerns and may have beneficial effects on some kidney-related outcomes.

Featured Image

Read the Original

This page is a summary of: Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials, Diabetes Care, April 2022, American Diabetes Association,
DOI: 10.2337/dc21-2034.
You can read the full text:

Read

Contributors

Be the first to contribute to this page